九五至尊网址

2020
May 2020

九五至尊网址NMPA accepted the application for anti PD-1 monoclonal antibody penpulimab (AK105)

Apr 2020

HKEX Listing(Stock Code: 9926)

2019
Aug 2019

九五至尊网址We established CTTQ-Akeso

Jun 2019

We formed Sino Biopharm Collaboration to codevelop and co-commercialize penpulimab (AK105)

We obtained the IND approval for a clinical trial of AK112 (PD-1/VEGF) in theUnited States

Mar 2019

We obtained the IND approval for AK104 from the FDA to begin a Phase Ib/II clinical trial in the United States

Jan 2019

九五至尊网址The Company was incorporated in the Cayman

Islands as an exempted company with limited liability

2018
May 2018

We initiated a Phase I clinical trial of ebronucimab (AK102) (PCSK9) in China

Mar 2018

We obtained the IND approval for penpulimab (AK105) with respect to cervical cancer and solid tumors from the FDA in the United States

Jan 2018

We initiated a Phase I clinical trial for AK101 (IL-12/IL-23)  in China

2017
Dec 2017

We initiated a Phase I clinical trial for penpulimab (AK105) (PD-1) in  Australia

Oct 2017

九五至尊网址We initiated a Phase I clinical trial (with chemotherapy) for AK104 (PD-1/CTLA-4) for the treatment of solid tumors in Australia

2015
Nov 2015

九五至尊网址We out-licensed AK107 (CTLA-4) to Merck (code name in Merck is MK1308)

2012
Apr 2012

We initiated the development of innovative ACE Platform and “TETRABODY” technology

Mar 2012

九五至尊网址Akeso Biopharma (中山康方生物醫藥有限公司), our principal operating entity, was established in Zhongshan, China

www.782.net-最新网址-九五至尊网址 8455娱乐场门新葡8455最新网站-九五至尊网址 357 cc拉斯维加斯3499-九五至尊网址 澳门新莆京98378com-九五至尊网址 澳门太阳集团2007登陆注册-九五至尊网址 新葡京集团 www.350.vip-九五至尊网址 永利402com官方网站手机版-九五至尊网址 澳门新葡亰平台游戏app官网九五至尊网址-九五至尊网址 95992222九五至尊老品牌-九五至尊网址 mg4155娱乐电子游戏官网-九五至尊网址 伟德betvictot手机版-九五至尊网址 188金宝搏亚洲体育app下载-九五至尊网址 vnsc5858威尼斯城官网-九五至尊网址 188金宝搏亚洲体育app-九五至尊网址 澳门威尼斯人官方网投电子游戏-九五至尊网址 js55658澳门金金沙平台-九五至尊网址 亚洲城vipca88手机版登陆-九五至尊网址 williamhill-九五至尊网址 澳门新葡350vip最新网站-九五至尊网址 95998888九五至尊在线-九五至尊网址